Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease

基因科技的Prasinezumab第二階段IIb研究未能達到主要終點，但在早期帕金森病中顯示出潛力。

Benzinga · 12/19 14:48

*– PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints –

*– PADOVA研究顯示運動進展的數值延遲，多個次要和探索性終點呈積極趨勢 –

– Prasinezumab continues to be well tolerated and no new safety signals were observed –

– Prasinezumab繼續被很好地耐受，沒有觀察到新的安全信號 –

– Genentech is further evaluating the data and will work together with health authorities to determine next steps –

– Genentech正在進一步評估數據，並將與衛生當局合作判斷下一步措施 –

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明